Safety and tolerability of donepezil, rivastigmine and galantamine for patients with alzheimer's disease: Systematic review of the 'real-world' evidence

Dementia and Geriatric Cognitive Disorders

Volumn 28, Issue 5, 2009, Pages 389-403

  Lockhart, I A ^a   Mitchell, S A ^b   Kelly, S ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b Decision Resources Group   (United Kingdom)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Real world setting

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; AGITATION; ALERTNESS; ALZHEIMER DISEASE; ANEMIA; CARDIOVASCULAR SYMPTOM; CENTRAL NERVOUS SYSTEM; CLINICAL PRACTICE; CLINICAL TRIAL; COCHRANE LIBRARY; COHORT ANALYSIS; CONFUSION; CONGESTIVE HEART FAILURE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBASE; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEART ARRHYTHMIA; HUMAN; INCIDENCE; INSOMNIA; IRRITABILITY; LETHARGY; LIMB WEAKNESS; LOW DRUG DOSE; LUNG DISEASE; MEDLINE; MUSCLE CRAMP; NAUSEA; NEUROLOGIC DISEASE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; REVIEW; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SYNCOPE; SYSTEMATIC REVIEW; VERTIGO; VOMITING;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; EVIDENCE-BASED MEDICINE; GALANTAMINE; HUMANS; INDANS; PHENYLCARBAMATES; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 70350673942     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000255578     Document Type: Review

References (51)

1. Solfrizzi V, D'Introno A, Colacicco AM, Capurso C, Del Parigi A, Capurso S, Gadaleta A, Capurso A, Panza F: Dietary fatty acids intake: Possible role in cognitive decline and dementia. Exp Gerontol 2005; 40: 257-270.
2. Burns A, O'Brien J: Clinical practice with anti-dementia drugs: A consensus statement from British Association for Psychopharmacology. J Psychopharmacol 2006; 20: 732-755.
3. Brookmeyer R, Gray S, Kawas C: Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88: 1337-1342.
4. House of Commons Committee of Public Accounts: Improving services and support for people with dementia: Sixth report of session 2007-2008. London, The Stationery Office, 2008.
5. King's College London and London School of Economics and Political Science: Dementia UK (Report to the Alzheimer's Society). London, Alzheimer's Society, 2007.
6. National Institute for Health and Clinical Excellence: Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (amended): NICE technology appraisal guidance 111 (amended). London, National Health Service, 2007.
7. Medicines Management Team NHS Lothian: Drugs not recommended by the Scottish Medicines Consortium (SMC). 2008. www. ljf.scot.nhs.uk/smc-lists/smc- not-recommended-drugs.pdf.
8. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE: Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: A systematic review and meta-analysis. Clin Interv Aging 2008; 3: 211-225.
9. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M: Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. Ann Intern Med 2008; 148: 379-397.
10. Kavirajan H, Schneider LS: Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: A metaanalysis of randomised controlled trials. Lancet Neurol 2007; 6: 782-792.
11. Fortin M, Dionne J, Pinho G, Gignac J, Almirall J, Lapointe L: Randomized controlled trials: Do they have external validity for patients with multiple comorbidities? Ann Fam Med 2006; 4: 104-108.
12. Rothwell PM: External validity of randomised controlled trials: 'to whom do the results of this trial apply?' Lancet 2005; 365: 82-93.
13. Brodaty H, Woodward M, Boundy K, Barnes N: Naturalistic treatment of Alzheimer's disease with galantamine: 12-month follow-up from the nature study. CNS Drugs 2007; 21: 335-336.
14. Gauthier S, Juby A, Morelli L, Rehel B, Schecter R: A large, naturalistic, community-based study of rivastigmine in mild-tomoderate AD: The extend study. Curr Med Res Opin 2006; 22: 2251-2265.
15. Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FCV, Maud CM, Engelbrecht I, Hock C, Ieni JR, Bahra RS: A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 2002; 56: 441-446.
16. Wilcock G, Howe I, Coles H, Lilienfeld S, Truyen L, Zhu Y, Bullock R, Kershaw P, GAL-GBR-2 Study Group: A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 2003; 20: 777-789. (Pubitemid 36995254)
17. Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R: Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005; 21: 1317-1327.
18. Harry RD, Zakzanis KK: A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: A meta-analysis. Hum 2005; 20: 183-187.
19. Kavirajan H, Schneider LS: Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: A metaanalysis of randomised controlled trials. Lancet Neurol 2007; 6: 782-792.
20. Takeda A, Loveman E, Clegg A, Kirby J, Picot J, Payne E, Green C: A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int J Geriatr Psychiatry 2006; 21: 17-28.
21. Wells G, Shea B, O'Connell D, Robertson J, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis.
22. The Cochrane Collaborative Review Group on HIV Infection and AIDS: Editorial policy: Inclusion and appraisal of experimental and non-experimental (Observational) Studies. http://www.igh.org/Cochrane/pdfs/ EP-inclusionquality. pdf.
23. Turon-Estrada A, Lopez-Pousa S, Gelada-Batlle E, Garre-Olmo J, Lozano-Gallego M, Hernandez-Ferrandiz M, Fajardo-Tibau C, Morante-Munoz V, Vilalta-Franch J: Tolerance and adverse events of treatment with acetylcholinesterase inhibitors in a clinical sample of patients with very slight and mild Alzheimer's disease over a six-month period. Rev Neurol 2003; 36: 421-424.
24. Sobow T, Kloszewska I: Cholinesterase inhibitors in the 'real world' setting: Rivastigmine versus donepezil tolerability and effectiveness study. Arch Med Sci 2006; 2: 194-198.
25. Hughes A, Musher J, Thomas SK, Beusterien KM, Strunk B, Arcona S: Gastrointestinal adverse events in a general population sample of nursing home residents taking cholinesterase inhibitors. Consult Pharm 2004; 19: 713-720.
26. Mossello E, Tonon E, Caleri V, Tilli S, Cantini C, Cavallini MC, Bencini F, Mecacci R, Marini M, Bardelli F, Sarcone E, Razzi E, Biagini CA, Masotti G: Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: A 'real world' study. Arch Gerontol Geriatr Suppl 2004; 9: 297-307.
27. Fuschillo C, Ascoli E, Franzese G, Campana F, Cello C, Galdi M, La Pia S, Cetrangolo C: Alzheimer's disease and acetylcholinesterase inhibitor agents: A two-year longitudinal study. Arch Gerontol Geriatr Suppl 2004; 9: 187-194.
28. Lopez-Pousa S, Turon-Estrada A, Garre-Olmo J, Pericot-Nierga I, Lozano-Gallego M, Vilalta-Franch M, Hernandez-Ferrandiz M, Morante-Munoz V, Isern-Vila A, Gelada-Batlle E, Majo-Llopart J: Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period. Dement Geriatr Cogn Disord 2005; 19: 189-195.
29. De La Gastine B, Mosquet B, Coquerel A: Assessment of adverse effects of Alzheimer's disease medications: Analysis of notifications to regional pharmacovigilance centers in northwest France. Revue de Geriatrie 2007; 32: 575-584.
30. Lleshi E, Nicod M, Coutaz M, Morisod J: Study of the prescription efficiency and tolerance of acetylcholinesterase inhibitors in Alzheimer's disease. Med Hyg (Geneve) 2004; 62: 1849-1856.
31. Aguglia E, Onor ML, Saina M, Maso E: An open-label, comparative study of rivastigmine, donepezil and galantamine in a realworld setting. Curr Med Res Opin 2004; 20: 1747-1752.
32. Raschetti R, Maggini M, Sorrentino GC, Martini N, Caffari B, Vanacore N: A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. Eur J Clin Pharmacol 2005; 61: 361-368.
33. Pakrasi S, Mukaetova-Ladinska EB, Mc-Keith IG, O'Brien JT: Clinical predictors of response to acetyl cholinesterase inhibitors: Experience from routine clinical use in Newcastle. Int J Geriatr Psychiatry 2003; 18: 879-886.
34. Shua-Haim JR, Pass MD, Patel S, Patel S, Lee P, Patel P: A head to head study of donepezil, rivastigmine, and galantamine for the treatment of Alzheimer's disease: Safety, tolerability, clinical and caregiver impressions after 9 months of treatment. Poster Int Conf Alzheimer's Dis, 2004.
35. Bianchetti A, Padovani A, Trabucchi M: Outcomes of Alzheimer's disease treatment: The Italian CRONOS project. Int J Geriatr Psychiatry 2003; 18: 87-88.
36. Bullock R, Truyen L: Not all head-to-head trials are created equal: Results from an openlabel, short-term study seem inconsistent with previous donepezil literature. Int J Geriatr Psychiatry 2005; 20: 85-87.
37. Brodaty H, Corey-Bloom J, Potocnik FCV, Truyen L, Gold M, Damaraju CRV: Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord 2005; 20: 120-132.
38. Jones RW, Soininen H, Hager K, Aarsland D, Passmore P, Murthy A, Zhang R, Bahra R: A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry 2004; 19: 58-67.
39. Rogers SL, Doody RS, Mohs RC, Friedhoff LT: Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158: 1021-1031.
40. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50: 136-145.
41. Wilkinson D, Murray J: Galantamine: A randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2001; 16: 852-857. (Pubitemid 32926767)
42. Wilcock GK, Lilienfeld S, Gaens E: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000; 321: 1445-1449.
43. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ 1999; 318: 633-638.
44. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D: Effects of a flexible galantamine dose in Alzheimer's disease: A randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001; 71: 589-595.
45. Joint Formulary Committee: British National Formulary, ed 57. London, British Medical Association and Royal Pharmaceutical Society of Great Britain, 2009.
46. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M: Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. Ann Intern Med 2008; 148: 379-397.
47. Kavirajan H, Schneider LS: Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: A metaanalysis of randomised controlled trials. Lancet Neurol 2007; 6: 782-792.
48. Ancoli-Israel S, Amatniek J, Ascher S, Sadik K, Ramaswamy K: Effects of galantamine versus donepezil on sleep in patients with mild to moderate Alzheimer disease and their caregivers: A double-blind, head-tohead, randomized pilot study. Alzheimer Dis Assoc Disord 2005; 19: 240-245.
49. Fuschillo C, La Pia S, Campana F, Pinto A, De Simone L: Cognitive deficits in Alzheimer's disease: Treatment with acetylcholinesterase inhibitor agents. Arch Gerontol Geriatr Suppl 2001; 7: 151-158.
50. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C: A 5-month, randomized, placebo-controlled trial of galantamine in AD: The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269-2276.
51. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, Van Bussche HD: Cholinesterase inhibitors for patients with Alzheimer's disease: Systematic review of randomised clinical trials. BMJ 2005; 331: 321-323.